Expeditious treatment of stage I melanoma is associated with improved outcomes, according to a recent study. Patients with stage I to III cutaneous melanoma and with available time to definitive surgery and overall survival were identified by using the National Cancer Database (n=153,218). The t test and chi-square test were used to compare variables; Cox regression was used for multivariate analysis. Researchers found:
- In a multivariate analysis, patients in all stages who were treated between 90 and 119 days after biopsy and >119 days had a higher risk for mortality compared with those treated within 30 days of biopsy.
- In a subgroup analysis of stage I, higher mortality risk was found in patients treated within 30 to 59 days, 60 to 89 days, 90 to 119 days, and >119 days after biopsy.
- Surgical timing did not affect survival in stages II and III.
Conic RZ, Cabrera CI, Khorana AA, Gastman BR. Determination of the impact of melanoma surgical timing on survival using the National Cancer Database. [Published online ahead of print October 17, 2017]. J Am Acad Dermatol. doi:10.1016/j.jaad.2017.08.039.
This Week's Must Reads
Must Reads in Melanoma
Melanoma Rates Before and After AJCC 7 Enactment, JAMA Dermatol; ePub 2019 Mar 6; Isom, et al
HLA Antigen Mismatch Linked with Skin Cancer Risk, JAMA Dermatology; ePub 2019 Jan 23; Gao, Twigg, et al
Poor Prognosis for Thin Ulcerated Melanomas Found, J Am Acad Dermatol; ePub 2019 Jan 14; Hawkins, et al